MedPath

Effect of Barberry on Non Alcoholic

Phase 2
Conditions
on-alcoholic Steatohepatitis.
Fatty (change of) liver, not elsewhere classified
Registration Number
IRCT201202068505N2
Lead Sponsor
Vice Chancellor for Research, Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Including criteria : older than 20 years with nonalcoholic- fatty liver disease; liver enzymes>42 and proportion of ALT/ AST>1. Excluding criteria : using drugs that affect liver tests during the last 2 months; viral hepatitis; hemochromatosis; autoimmune hepatitis; cirrhosis;type 1 diabetes; alcohol dependency; pregnancy; breast feeding and infectious diseases

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ALT. Timepoint: Before, 45 days and 3 month after the therapy. Method of measurement: Laboratory.;AST. Timepoint: Before, 45 days and 3 month after the therapy. Method of measurement: Laboratory.;FBS. Timepoint: Before, 45 days and 3 month after the therapy. Method of measurement: Laboratory.
Secondary Outcome Measures
NameTimeMethod
Chol-T. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.;Triglycirid. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.;LDL. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.;HDL. Timepoint: Before and 3 months after the therapy. Method of measurement: laboratory.
© Copyright 2025. All Rights Reserved by MedPath